Faropenem Antibiotic Coverage
Faropenem is an oral penem antibiotic with broad-spectrum activity against most Gram-positive and Gram-negative aerobes and anaerobes, including extended-spectrum beta-lactamase (ESBL) producers, but it lacks activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. 1
Antimicrobial Spectrum
Gram-Positive Coverage
- Streptococcus pneumoniae: Highly active (MIC₉₀ ≤2 mg/L) 2
- Methicillin-susceptible Staphylococcus aureus (MSSA): Excellent activity (MIC TECOFF 0.25 mg/L) 2
- Streptococcal species: Potent activity against aerobic Gram-positive bacteria 3
- Actinomyces species: Highly active (MIC₉₀ ≤0.5 mg/L) 4
- Does NOT cover MRSA - this is a critical limitation 1
- Does NOT cover vancomycin-resistant E. faecium 1
Gram-Negative Coverage
- Escherichia coli: Excellent activity including ESBL producers (MIC TECOFF 2 mg/L, with >95% of ESBL producers susceptible at ≤2 mg/L) 5, 2
- Klebsiella pneumoniae: Good activity against ESBL producers (MIC TECOFF 2 mg/L), though some strains show reduced susceptibility 5, 2
- Haemophilus influenzae: Active (MIC TECOFF 1 mg/L) 2
- Enterobacter species: Moderate activity against ESBL producers, but less active against AmpC-derepressed strains (modal MICs 2-4 mg/L, with ~5% requiring ≥16 mg/L) 5
- Citrobacter species: Similar to Enterobacter 5
- Serratia species: Limited activity, especially against AmpC-derepressed strains (MICs 8-16 mg/L) 5
- Does NOT cover Pseudomonas aeruginosa - critical gap 1
- Does NOT cover Stenotrophomonas maltophilia 1
Anaerobic Coverage
Faropenem demonstrates excellent anaerobic activity comparable to imipenem and meropenem 6:
- Bacteroides fragilis group: Highly active (MIC₅₀/₉₀ 0.12/1 mg/L), with only 1.1% resistance 6
- Porphyromonas gingivalis: Highly active (MIC₉₀ ≤0.5 mg/L) 4
- Prevotella species: Excellent activity 4
- Fusobacterium nucleatum: Highly active 4
- Peptostreptococcus species: Excellent activity 4
- All Gram-negative anaerobes: MIC₅₀/₉₀ 0.12/1 mg/L 6
- All Gram-positive anaerobes: MIC₅₀/₉₀ 0.25/1 mg/L 6
Key Resistance Characteristics
Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including ESBLs (particularly CTX-M types) and AmpC beta-lactamases 1, 5. This makes it particularly valuable against community-acquired ESBL-producing E. coli and Klebsiella species. However, carbapenemases (NMC-A Class A and IMP Class B) substantially raise faropenem MICs 5.
Clinical Implications
The spectrum positions faropenem as an oral alternative for infections caused by ESBL-producing Enterobacteriaceae, particularly urinary tract infections where drug concentrations are highest 5. Its broad anaerobic coverage makes it suitable for polymicrobial infections involving oral or gastrointestinal flora 4.
Critical Gaps to Remember:
- No MRSA coverage - add vancomycin, linezolid, or daptomycin if suspected
- No Pseudomonas coverage - use antipseudomonal beta-lactams or fluoroquinolones if at risk
- Variable activity against AmpC-hyperproducing Enterobacter/Serratia - consider alternatives for severe infections with these organisms
- No VRE coverage - requires alternative agents
Antimicrobial Stewardship Concerns
The convenience of oral administration creates significant risk for overuse, which may promote cross-resistance with parenteral carbapenems (meropenem, imipenem), rendering them ineffective 7. Faropenem should be reserved for documented ESBL infections or situations where narrower-spectrum oral agents are inappropriate, not used as first-line empiric therapy for common community-acquired infections 8, 7.